Search

A study conducted at the Memorial Sloan-Kettering Cancer Center in New York City examined the impact of new onset atrial fibrillation (AF) compared to preexistent AF in hospitalized patients with cancer. The study found that patients with new onset AF had a higher risk for adverse outcomes, including all-cause death, cardiovascular rehospitalization, and cerebrovascular events, compared to patients with preexistent AF. The findings suggest that new onset AF in cancer patients may have a significant clinical impact. Further research is needed to better understand the relationship between AF and cancer outcomes. [Extracted from the article]

A study conducted by researchers at the Icahn School of Medicine at Mount Sinai in New York City aimed to investigate the incidence, predictors, and impact of hospital readmissions following revascularization for left main coronary artery disease (LMCAD). The study analyzed data from the EXCEL trial, which included 1,905 patients with LMCAD who were randomized to receive either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The findings revealed that readmissions were common within 5 years after revascularization, with PCI patients experiencing more readmissions than CABG patients. Additionally, readmissions were associated with a higher risk of all-cause death, particularly after PCI. [Extracted from the article]

A study conducted at Memorial Sloan-Kettering Cancer Center in New York City examined the feasibility and safety of breast MRI exams and guided biopsies in patients with an implantable loop recorder (ILR). The study found that breast MRI is feasible and safe for patients with ILR, although it may produce localized artifacts that can affect image interpretation. The researchers concluded that breast MRI in these patients may provide significant diagnostic value. The study was supported by the NIH/NCI Cancer Center Support Grant and has been peer-reviewed. [Extracted from the article]

A recent study conducted at Mayo Clinic Rochester explored the use of artificial intelligence (AI) in predicting outcomes for patients undergoing autologous hematopoietic cell transplantation (auto HCT) for plasma cell disorders (PCD). The researchers developed AI-ECG tools that were trained to predict comorbidity and evaluated them using data from 849 patients who underwent auto HCT. The study found that AI-ECG was able to predict the risk of atrial fibrillation/flutter (AF) and other cardiac outcomes, and correlated with the incidence of post HCT AF. The researchers concluded that AI-ECG could enhance risk prediction for cardiac-specific outcomes in patients undergoing auto HCT for PCD. [Extracted from the article]

2021 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Heart Disorders and Diseases - Heart Failure have been [...]

2021 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Heart Disorders and Diseases - Atrial Fibrillation. [...]

2020 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Heart Disorders and Diseases - Heart Attack have been [...]